Clearly CHF,DDD,Spinal Fusion, Cord Blood and Prochymal(GVHD & Crohn's) are MSB's lead applications - at this stage...which is in accordance with the Professors presentations.
The professor was on point in the Dec 13 ASX release when he stated that “This is an important first step in developing an MPC-based immunomodulatory therapy
for the treatment of type 2 diabetes and its complications.”
Based on previous MSB announcements (26/6/13),the principal complication of type 2 diabetes is diabetic kidney disease. The current 30 patient P2 trial relating to diabetic nephropathy (chronic kidney disease) is ongoing with updates expected in CL14.
Here is a couple of comments made by analysts(life sciences report) re T2d and the topline results announced in December 2013.
Jason Kolbert, Maxim Group (12/4/13) "Mesoblast Ltd. announced topline results from its phase 2 trial of its allogeneic stem cell therapy in type 2 diabetic patients. . .this is yet another example, of data, that these cells are active, safe and, in the right setting, effective."
Kevin DeGeeter, Ladenburg Thalmann (12/4/13) "On Dec. 3, 2013, Mesoblast Ltd. disclosed positive topline results from a phase 2 study of the company's mesenchymal precursor cells in patients with type 2 diabetes. Importantly, the data significantly increase our confidence in a positive outcome for Mesoblast's ongoing phase 2 study in a related disorder, diabetic nephropathy."
Cheers to all holders (dyor).
t2d - very interesting...but, page-12
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.06 | $8.816M | 8.055M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 280000 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |